Objective. To identify initial predictors of poor survival in patients with PM/DM-associated interstitial lung disease (ILD).
Introduction
PM and DM are autoimmune conditions classified into a group of idiopathic inflammatory myopathies that target muscle, skin, joints and lungs to various degrees [1] . Interstitial lung disease (ILD) is a life-threatening complication in PM/DM [2] . The clinical course and treatment response of PM/DM-associated ILD are quite heterogeneous, with the most devastating form being rapidly progressive ILD (RP-ILD), which is often resistant to immunosuppressive treatment [3, 4] . Approximately half of the patients who develop RP-ILD die despite intensive immunosuppressive treatment [5, 6] . Although an evidence-based treatment strategy has not been established for RP-ILD, studies suggest that it may be beneficial to introduce intensive immunosuppressive therapy, such as high-dose CS in combination with immunosuppressive agents, at an early stage of the disease, before the lungs are irreversibly damaged [7, 8] . Thus, it is critical to identify predictive factors of poor survival in patients with PM/DM-associated ILD.
A number of studies have examined potential risk factors associated with poor survival in patients with PM/DMassociated ILD, and have reported associations between poor outcomes and older age, DM classification, skin ulceration, pneumomediastinum and a lack of myositis [911] . Among the myositis-specific autoantibodies (MSAs), anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with ILD, but RP-ILD is more likely to be associated with anti-MDA5 antibody [5, 6, 12, 13] . A series of studies have reported that anti-MDA5 antibody, acute or subacute ILD onset, fever, higher serum ferritin levels, decreased circulating lymphocyte counts, elevated serum CRP and a lower consolidation/ground-glass attenuation (GGA) pattern on chest high-resolution CT (HRCT) are independent risk factors for predicting the course of RP-ILD or mortality [1419] . While anti-MDA5 antibody is consistently reported as a poor survival factor in most studies [13] , other reported prognostic factors are less consistent, probably due to the small sample sizes of these single-centre studies and to differences in patient populations between studies. To overcome these limitations, it was necessary to design a large-scale, welldefined, multicentre cohort.
To that end, we established the Multicentre Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI), which involved 44 institutions across Japan with a wide range of specialties, including rheumatology, respirology and dermatology. Information for the cohort was collected from demographic, clinical, imaging and laboratory data at the time of diagnosis, as well as autoantibody profiles, and the clinical course was retrospectively and/or prospectively recorded. Using the data from 497 incident cases of adult PM/DM-associated ILD registered in the JAMI database, we identified initial factors that predict mortality from respiratory insufficiency due directly to ILD.
Methods

Patients
JAMI is a multicentre retrospective cohort that allowed collaborative research on PM/DM-associated ILD. Investigators in individual participating centres were asked to enrol incident PM/DM-associated ILD cases who visited their centres between October 2011 and 2015. The inclusion criteria were as follows: an age at disease onset 516 years; definite or probable PM/DM according to the criteria proposed by Bohan and Peter [20] or clinically amyopathic DM (CADM) according to the criteria proposed by Sontheimer [21] ; the presence of ILD, based on the American Thoracic Society criteria and a multidisciplinary assessment of clinical, radiologic and pathologic findings [22] ; and availability of serum samples at diagnosis for comprehensive MSA analysis. At enrolment, data were collected retrospectively in a dedicated electronic database by a reference clinician in each centre. To evaluate outcomes, follow-up survival data, any diagnosis of malignancy and the cause of death if deceased were collected prospectively. This study was approved by the Ethics Committee of the coordinating centre (Nippon Medical School, Tokyo, Japan; 26-03-434) and by individual participating centres. All clinical information was obtained after the patients had given their informed consent. The JAMI cohort is registered in the University Hospital's Medical Information Network Clinical Trial Registry (UMIN000018663).
JAMI database
At enrolment, demographic, clinical, laboratory and imaging information at the time of diagnosis, before beginning immunosuppressive treatment, was inputted. The following demographic and clinical data were collected: gender, age at disease onset, body weight, height, postal code of residence at disease onset, disease duration at diagnosis, initial symptoms related to the disease, disease classification (PM, classic DM or CADM), fever, arthritis/arthralgia, Raynaud's phenomenon, sclerodactyly, sicca, muscle weakness, myalgia, Gottron's papules, Gottron's sign, palmar papules, heliotrope rash, shawl sign, neck V-sign, flagellate erythema, skin ulceration, periungual erythema, mechanic's hands and subcutaneous calcinosis. Peripheral blood laboratory results were recorded, including creatine kinase, aldolase, CRP, ESR, Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D), ferritin, Raynaud's phenomenon and ANAs on IIF. Findings on electromyography, MRI of extremities, chest radiograph, chest HRCT, peripheral capillary oxygen saturation (SpO 2 ), arterial blood gas analysis, forced vital capacity, forced expiratory volume in 1 s, diffusing capacity for carbon monoxide, 6-min walking distance, and pathologic findings of skeletal muscle, skin and lung were also collected when available. Chest HRCT findings were classified into four patterns according to Tanizawa et al. [23] : lower lobe consolidation/GGA, lower lobe reticulation, random GGA and others. The induction treatment regimen was also recorded, including CS (with starting dosage), CS pulse therapy, CYC, CSA, tacrolimus, MTX, AZA, MMF, IVIG and other treatments. A prednisolone equivalent of 550 mg daily was regarded as high-dose CS. We examined the patient's records from diagnosis until the last visit, and recorded the cause of death if the patient was deceased.
MSA detection
Serum samples were stored at À20˚C until use. MSAs were identified centrally at laboratories with the proper expertise at Tokai University, Keio University or Nippon Medical School. Anti-ARS antibodies were detected by RNA immunoprecipitation assay using K562-cell extracts as described previously [24] . Anti-ARS antibody results were judged positive when the given serum samples precipitated RNA components identical to those precipitated by the prototype sera positive for anti-Jo-1, anti-EJ, anti-OJ, anti-PL-7, anti-PL-12 or anti-KS. The anti-MDA5 antibody was measured by an in-house ELISA using recombinant MDA5 as an antigen source [25] .
Statistical analysis
We conducted univariate and multivariate analyses to identify predictive factors of mortality due to respiratory insufficiency directly related to PM/DM-associated ILD. Continuous values were shown as the median and 2.597.5 percentile. All statistical analyses were performed by an independent medical statistician (K.M.) using SPSS Statistics version 23 (IBM, Tokyo, Japan).
We conducted univariate analysis by Kaplan-Meier analysis with the Breslow test to compare the equality of survival curves for individual variables for demographic, clinical, laboratory, imaging and autoantibody parameters at diagnosis. Variables with available data for fewer than 350 cases were excluded from analysis. All continuous variables were converted to dichotomous variables for analysis, and cut-off values were determined by receiveroperating characteristics [26] . Multiple dichotomous variables were used for diagnosis (PM, classic DM or CADM) or MSAs (anti-MDA5
. The cause-specific Cox proportional hazards model was used for multivariate analysis to identify an optimal model for predicting poor survival caused by respiratory insufficiency. In some cases, we applied subdistribution hazards model, and/or imputed all missing values of dichotomous variables using a multiple imputation method and resultant generation of 1000 multiple imputation data sets, to verify the original model. During the stepwise selection process, sex, age at diagnosis and anti-MDA5 and anti-ARS antibodies were first adopted into the model, and all other variables at the time of diagnosis with P < 0.2 in the univariate analysis were subsequently entered into the model as potential predictors. Backward deletion (P 5 0.15) and forward inclusion (P < 0.1) were performed using the likelihood test to select the predictor variables in the model. Finally, selected induction treatment drugs were included in the final multivariate model as potential confounders. The results were shown as the hazard ratio (HR) with a 95% CI.
Results
Baseline characteristics
Of 499 patients registered, 2 were excluded because of incomplete data during the follow-up period, and 497 incident cases were enrolled in the study. The baseline characteristics of the cohort (available data 5350) are shown in Table 1 . The disease duration at diagnosis was 3 months (2.597.5 percentile 162), indicating that most patients were diagnosed and treated at an early stage. Our cohort consisted mainly of classic DM and CADM; only 15% were classified as PM. Muscle weakness was detected in 48%. Chest HRCT findings were available for 496 patients: a lower consolidation/GGA pattern was most prevalent, followed by lower reticulation and random GGA patterns. There were 166 patients (34%) with anti-ARS antibodies; 44 with anti-Jo-1, 41 with anti-EJ, 13 with anti-OJ, 32 with anti-PL-7, 26 with anti-PL-12 and 12 with anti-KS. Two patients had two anti-ARS specificities simultaneously: one was positive for anti-Jo-1 and anti-EJ, and the other for anti-Jo-1 and anti-PL-7. Anti-MDA5 was detected in 209 patients (42%). Although anti-ARS and anti-MDA5 antibodies were mutually exclusive in general, two patients had both (anti-PL-7 or anti-KS in one each). The detailed clinical course of one such patient is published elsewhere [27] . [28] .
Patient outcomes
The median observation period was 20 months (2.597.5 percentile 150), during which 93 patients died. The cause of death was respiratory insufficiency directly related to PM/DM-associated ILD in 76 (82%), infection in 5 (5%), malignancy in 5 (5%), and other causes such as renal insufficiency, cardiomyopathy and suicide in 7 (8%). Thus, the majority of deaths in the JAMI cohort were directly due to ILD.
Initial predictors of mortality due to ILD
We examined initial predictors at the time of diagnosis of mortality directly due to ILD by univariate analysis of all initial variables (excluding induction treatment regimens) with available data for 350 or more cases. Table 2 lists initial parameters significantly associated with ILD mortality. The following initial parameters were identified as predictors for poor ILD outcomes: male, older age at disease onset (560 years), CADM, classic DM, fever, neck V-sign, skin ulceration, periungual erythema, higher CRP (51 mg/ dl), higher KL-6 (51000 U/ml), higher ferritin (5500 ng/ml), lower consolidation/GGA and random GGA patterns on chest HRCT, lower SpO 2 (<95%) and anti-MDA5 antibody. In contrast, favourable ILD outcomes were associated with Raynaud's phenomenon, muscle weakness, higher creatine kinase, higher aldolase, higher SP-D and anti-ARS antibody. It was of note that the majority of predictors for ILD outcomes identified in univariate analysis were associated with anti-MDA5 antibody (supplementary Table S1 , available at Rheumatology online).
To generate an appropriate predictive model for mortality due to PM/DM-associated ILD, we conducted multivariate analysis using a stepwise selection of parameters and the cause-specific Cox proportional hazards regression model to identify independent predictors. Sex, age at diagnosis, anti-MDA5 antibody and anti-ARS antibody were first adopted into the model, since demographic features and MSAs are reported as a poor survival factor in most previous studies [919] . Subsequently, all other initial variables with P < 0.2 in the univariate analysis were sequentially included in the model, and the number of variables was reduced by repeating the step-up and step-down procedure. Fig. 1 shows a final predictive model of mortality derived from 349 patients in whom all variable data were available, consisting of nine independent variables. In particular, age at disease onset 560 years (HR = 4.3, 95% CI: 2.4, 7.5; P < 0.001), anti-MDA5 antibody (HR = 7.5, 95% CI: 2.8, 20.2; P < 0.001), CRP 51 mg/dl (HR = 2.6, 95% CI: 1.5, 4.8; P = 0.001) and SpO 2 <95% (HR = 2.0, 95% CI: 1.2, 3.4; P = 0.011) were selected as independent risks for ILD mortality. The identical variables were selected when subdistribution hazards model was applied (supplementary Table S2 , available at Rheumatology online).
When we included the drugs used for induction treatment (including high-dose CS, the calcineurin inhibitors CSA or tacrolimus, CYC and IVIG) in the final multivariate model as potential confounders, the four independent risk factors remained statistically significant: age at onset (HR = 3.8, 95% CI: 2.2, 6.7; P < 0.001), anti-MDA5 antibody (HR = 6.5, 95% CI: 2.3, 17.9; P < 0.001), CRP (HR = 2.6, 95% CI: 1.5, 4.7; P = 0.001) and SpO 2 (HR = 2.1, 95% CI: 1.2, 3.5; P = 0.005), while KL-6 51000 U/ml was additionally selected as an independent risk factor (HR = 2.0, 95% CI: 1.2, 3.3; P = 0.01). Fig. 2 shows Kaplan-Meier analyses comparing the equality of cumulative survival curves between two groups stratified by individual prognostic factors. The cumulative survival rates were significantly different (P < 0.01 for all comparisons), and this difference was apparent even early in the course of the disease because of deaths due to RP-ILD. The survival curves for the low and high SP-D groups intersected at 80 months, indicating possible violation in proportional hazards model. Exclusion of SP-D from the explanatory variables resulted in the selection of age at onset, anti-MDA5 antibody and CRP as variables for ILD mortality (supplementary Fig. S1 , available at Rheumatology online). Since there were several missing variables in our database, a multiple imputation method was applied to confirm the model validity (supplementary Fig. S2 , available at Rheumatology online). The significant variables obtained were principally identical, and included age at disease onset, anti-MDA5 antibody, CRP, KL-6 and SpO 2 .
Because 67 (88%) deaths occurred in anti-MDA5-positive patients, our model was likely to depend heavily on the anti-MDA5 antibody. To assess this possibility, we generated predictive models for the mortality, separately in patients with and without anti-MDA5 antibody. Two patients with coexisting anti-MDA5 and anti-ARS antibodies were included in the anti-MDA5-positive group. As shown in supplementary Table S3 , available at Rheumatology online, and Fig. 3A , in anti-MDA5-positive patients, age at disease onset 560 years and CRP 51 mg/dl were again significant explanatory variables for ILD mortality risk, while periungual erythema was identified as a favourable predictor. The same variables were selected when a multiple imputation method was applied (supplementary Fig. S3A , available at Rheumatology online). In contrast, no significant explanatory variable for ILD mortality risk was identified in anti-MDA5-negative patients, regardless of the absence (supplementary Table S4 , available at Rheumatology online; Fig. 3B ) or the presence of a multiple imputation method (supplementary Fig. S3B , available at Rheumatology online), but there were trends toward a correlation between ILD mortality risk and age at disease onset 560 years or CRP 51 mg/dl.
Discussion
In this study, we used the large-scale JAMI database to identify initial predictors for mortality due to respiratory insufficiency in adult patients with PM/DM-associated ILD. A number of factors at diagnosis were selected by univariate analysis, but cause-specific Cox proportional hazards models revealed the following to be predictors independently associated with future poor mortality due   FIG. 1 Predictive model for mortality due to respiratory insufficiency in patients with PM/DM-associated ILD Initial predictors of poor prognosis due to fatal respiratory insufficiency were identified by multivariate analysis using a stepwise selection of parameters and the causespecific Cox proportional hazards regression model. The hazard ratio with 95% CI is shown for each variable finally selected. ILD: interstitial lung disease; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein; ARS: aminoacyl; MDA5: melanoma differentiation-associated gene 5.
to ILD: age at disease onset, anti-MDA5 antibody, CRP and SpO 2 . This final model was verified by a variety of different models. Since age, CRP and SpO 2 are readily available in routine clinical practice, and kits to measure the anti-MDA5 antibody are now commercially available [29, 30] , our findings are widely applicable for identifying PM/DM patients with intractable ILD who require intensive treatment at an early stage. Our results will also assist in designing appropriate patient inclusion criteria for future clinical trials for PM/DM-associated ILD.
JAMI is a nationwide, large-scale cohort established in Japan. It is the first multicentre cohort focusing on PM/ DM-associated ILD, although there are several multicentre cohorts of patients with idiopathic inflammatory myopathy [31, 32] , juvenile-onset myositis [33] and anti-synthetase syndrome [34, 35] . The patient population might vary between specialties, because the clinical presentation of PM/ DM is quite heterogeneous; patients with progressive or advanced ILD with significant respiratory distress are likely to be referred to pulmonologists or critical care physicians, while those whose predominant symptom is skin rashes are often referred to dermatologists. Therefore, patients in the JAMI cohort are cared for by a wide variety of specialties to avoid potential patient selection bias. Finally, because serum samples obtained at the time of diagnosis were available for all patients, we were able to run assays for a full panel of MSAs. These features give the JAMI cohort several advantages for analysing various clinical aspects of PM/DM-associated ILD.
This study confirmed many prognostic factors reported in previous studies, including gender, age at disease onset, CADM, classic DM, fever, skin ulceration, periungual erythema, muscle weakness, creatine kinase, ferritin, chest HRCT patterns, SpO 2 , anti-MDA5 antibody and anti-ARS antibody, although the populations and endpoints were somewhat different among studies [919] . Since many of these factors are correlated with each other, it is difficult to identify primary contributing factors from previous studies, primarily because of small sample sizes. In fact, in our cohort, the majority of these factors were not selected as independent predictors in multivariate analysis. Our predictive modelling successfully identified age at disease onset, CRP and anti-MDA5 antibody as independent initial predictors of poor ILD prognosis. In particular, anti-MDA5 antibody provided the highest HR, with a 7.5-fold increase in risk. In fact, the other prognostic factors were associated with anti-MDA5 antibody, and were mostly relevant to anti-MDA5-positive patients who dominated the analysis, since we failed to identify risk for ILD mortality in patients without anti-MDA5 antibody, probably because of the small number of deaths. This finding is consistent with a meta-analysis of 13 studies that found a pooled sensitivity and specificity of anti-MDA5 antibody for RP-ILD of 77 and 86%, respectively, in DM patients [36] .
In contrast, we found that anti-ARS antibody tended to predict favourable ILD outcomes, at least in the short term, although this is likely a reflection of the strong association between anti-MDA5 antibody and poor prognosis. In this regard, a previous study found no significant increase in mortality in patients with anti-synthetase syndrome compared with the general US population [37] . In addition, Yoshida et al. [38] reported that the anti-MDA5 antibody is associated with a higher 3-month mortality compared with the anti-ARS antibody. Thus, MSA measurement at diagnosis is highly useful for predicting treatment responses and outcomes in patients with PM/DM-associated ILD.
The prognostic significance of CRP in patients with PM/ DM-associated ILD has not been emphasized in the literature, although a recent meta-analysis indicated that CRP is associated with an increased risk of developing ILD in PM/DM patients [39] . Notably, in a small Chinese study of 40 patients with CADM, multivariate logistic regression analysis showed that anti-MDA5 antibody combined with elevated CRP is an independent risk factor for developing RP-ILD [15] . Interestingly, CRP is a prognostic factor for other forms of ILD, such as biopsy-proven idiopathic pulmonary fibrosis [40] and SS-associated ILD [41] , suggesting that this biomarker might reflect inflammation in the lung parenchyma that leads to irreversible damage.
Since JAMI is a retrospective cohort, management was determined by attending physicians, who were unaware of the MSA data. In addition, the treatment regimens for the JAMI cohort were considerably different from those in previous reports. The JAMI patients were often treated with calcineurin inhibitors and a 'triple combo' consisting of high-dose CS, CYC and calcineurin inhibitor. IVIG and polymyxin B-immobilized fibre column-direct haemoperfusion were occasionally administered on top of immunosuppressive regimens [42, 43] . MMF or rituximab was seldom used, potentially contributing to worse survivals in our cohort. The selections of treatment regimens are different from those in other countries, primarily due to Japan's unique health insurance system. Although these treatment regimens had the potential to influence patient outcomes, our multivariate model consistently selected the same independent prognostic factors even after adjusting for the drugs used in induction treatment as potential confounders.
The present study has potential limitations due to its retrospective nature. Patients were selected mainly from tertiary referral hospitals, so there may be a bias toward more severe forms of the disease. However, the nature of a multicentre study and the inclusion of dermatology centres may minimize this bias. In addition, because the observation period after diagnosis was a median of 20 months, our current analysis only detected predictors for short-term mortality. This feature might have caused us to overestimate the importance of the anti-MDA5 antibody due to its strong association with RP-ILD. Long-term outcomes can be assessed as more follow-up data become available. Finally, information on smoking was not included in the JAMI database, because it has never been reported as a poor prognostic factor in patients with PM/DM-associated ILD. However, a recent multicentre registry of patients with idiopathic inflammatory myopathy (EuroMyositis) found an association of smoking with ILD [31] , urging us to examine a potential influence of smoking habits on ILD prognosis in the JAMI cohort as a future project.
In conclusion, we successfully generated a model to predict ILD mortality in patients with PM/DM-associated ILD at diagnosis, based on a newly established multicentre cohort. Our findings are easily applied to routine care, and may help to identify patients who are at high risk for ILD mortality and require immediate intensive treatment.
FIG. 3
Predictive models for mortality due to respiratory insufficiency in patients with and without anti-MDA5 antibody Initial predictors of poor prognosis due to fatal respiratory insufficiency were identified in patients with anti-MDA5 antibody (A) and in those without anti-MDA5 antibody (B), by multivariate analysis using a stepwise selection of parameters and the cause-specific Cox proportional hazards regression model. The hazard ratio with 95% CI is shown for each variable finally selected. ILD: interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; ARS: aminoacyl.
